Recro Pharma (REPH) Tops Q3 EPS by 6c, Revenues Beat; Raises 2018 CDMO Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Recro Pharma (REPH) Tops Q3 EPS by 6c, Revenues Beat; Raises 2018 CDMO Guidance
November 7, 2018 7:00 AM EST
Company to Host Conference Call Today at 8:00 AM ET
MALVERN, Pa., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ: REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today reported financial results for the three months and nine months ended September 30, 2018.
With the PDUFA goal date now set for March 24, 2019, we are focusing our resources and efforts on preparing for our first potential product launch during the first half of 2019, said Gerri Henwood, President and Chief... More
November 7, 2018 7:00 AM EST
Company to Host Conference Call Today at 8:00 AM ET
MALVERN, Pa., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ: REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today reported financial results for the three months and nine months ended September 30, 2018.
With the PDUFA goal date now set for March 24, 2019, we are focusing our resources and efforts on preparing for our first potential product launch during the first half of 2019, said Gerri Henwood, President and Chief... More
